GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » Debt-to-EBITDA

Parnax Lab (BOM:506128) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Parnax Lab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Parnax Lab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Parnax Lab's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹243 Mil. Parnax Lab's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Parnax Lab's Debt-to-EBITDA or its related term are showing as below:

BOM:506128' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.31   Med: 3.42   Max: 7.38
Current: 2.54

During the past 13 years, the highest Debt-to-EBITDA Ratio of Parnax Lab was 7.38. The lowest was 2.31. And the median was 3.42.

BOM:506128's Debt-to-EBITDA is ranked worse than
60.51% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BOM:506128: 2.54

Parnax Lab Debt-to-EBITDA Historical Data

The historical data trend for Parnax Lab's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnax Lab Debt-to-EBITDA Chart

Parnax Lab Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 7.38 5.86 2.97 2.31

Parnax Lab Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.76 - 2.68 -

Competitive Comparison of Parnax Lab's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnax Lab's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Parnax Lab's Debt-to-EBITDA falls into.



Parnax Lab Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Parnax Lab's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(393.846 + 153.345) / 237.055
=2.31

Parnax Lab's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 242.756
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Parnax Lab  (BOM:506128) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Parnax Lab Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Parnax Lab's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnax Lab (BOM:506128) Business Description

Traded in Other Exchanges
N/A
Address
104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines